

M. A. Osborne
J.M. Eddleston
W. McNicoll

Inorganic fluoride concentration after long-term sedation with isoflurane

Received: 9 February 1995
Accepted: 10 January 1996

M.A. Osborne (✉)
Intensive Care Unit,
Withington Hospital, Nell Lane,
Manchester M20 2LR, UK

J.M. Eddleston · W. McNicoll
Critical Care Unit,
Manchester Royal Infirmary,
Oxford Road, Manchester M13 9WL, UK

Abstract We report on five patients in whom long-term sedation with isoflurane for up to 7 days was used successfully. Serum inorganic fluoride concentrations were measured daily. The concentrations ranged from 12 mmol l^{-1} to 29 mmol l^{-1} . These were well below the described renal toxic level of 50 mmol l^{-1} . There was no deterio-

ration in renal function attributable to the use of isoflurane.

Key words Isoflurane · Inorganic fluoride · Sedation · Intensive care

Introduction

The choice of a sedative agent for a critically ill patient can be difficult. Pharmacokinetic and pharmacodynamic changes which occur in this patient population can predispose to drug and metabolite accumulation and tachyphylaxis. Isoflurane has been suggested as an alternative. It possesses many of the properties of the ideal agent. Its rapidity of onset and offset, and minimal cumulation or metabolism within the body, give ease of control sedation. Its major disadvantages are its cost and potential for environmental pollution.

Kong et al. [1] demonstrated its safety up to 24 h in critically ill patients, and there have been several other reports [2, 3] of its clinical efficacy and safety in this patient population for up to 72 h.

However, some fear has been expressed regarding the accumulation of fluoride after prolonged use [4, 5]. Such accumulation is suspected of producing impairment of renal function, as was reported following the use of methoxyflurane [6].

Few reports relating to the use of isoflurane in intensive care have mentioned the measurement of serum fluoride concentrations. We report on the effect on the serum fluoride concentration after prolonged use of isoflurane for sedation in five critically ill patients (Ta-

ble 1). The analysis was performed using an ion-specific electrode for fluoride (EDT London, UK).

Patient A

This 52-year-old obese man was admitted to the intensive care unit (ICU) with severe necrotizing pancreatitis. The serum amylase was $>15000 \text{ IU l}^{-1}$. He required mechanical ventilation of the lungs, and ultimately his clinical course was complicated by the develop-

Table 1 Serum fluoride concentration ($\mu\text{mol l}^{-1}$). Day 1 = start of sedation with isoflurane. Coefficient of variation of results $<5\%$

Day	Patients				
	1	2	3	4	5
Pre-isoflurane			2.1	2.4	
2			11.8		
3	11.8		23.0		
4	13.4	10.9	27.9		
5	12.5	13.4			8.4
6	15.6				
7	13.0	20.7		23.3	12.3
8 ^a	10.2				

^a 24 h after discontinuation of isoflurane

Fig. 2 Patient B. The drugs given for sedation on a daily basis with the day after admission displayed across the top. All drug doses are in $\mu\text{g}/\text{kg}$ per min except isoflurane, which is shown as a percentage. Serum creatinine is in $\mu\text{mol}/\text{l}$

PATIENT B	
DAYS AFTER ADMISSION	
	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
INFUSION RATE	
MIDAZOLAM	1.1 2.7 2.7 2.7 2.8 2.8 2.8 2.8 2.5 2.2 1.9
FENTANYL	.08 .12 .15 .16 .04 .04 .04 .04 .05 .05
ISOFLURANE(%)	0.8 0.7 0.9 0.8 0.9 0.8
MORPHINE $\mu\text{g}/\text{kg}/\text{min}$	1.1 1.1 0.9 0.9 0.9 0.6 0.6
SEDATION SCORE	12 11 10 12 5 5 5 6 6 8 6 10 9 10 8 8 6
SERUM CREATININE	68 67 50 78 54 44 52 56 52 55 69 67 92 76 84 79

Fig. 3 Patient C. The drugs given for sedation on a daily basis with the day after admission displayed across the top. All drug doses are in $\mu\text{g}/\text{kg}$ per min except isoflurane, which is shown as a percentage. Serum creatinine is in $\mu\text{mol}/\text{l}$

PATIENT C	
DAYS AFTER ADMISSION	
	7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
INFUSION RATE	
MIDAZOLAM	4.8 5.2 6.3 6.3 2.1 2.6 2.6 1.4
MORPHINE	4.0 5.2 5.2 5.7
ISOFLURANE (%)	0.6 0.7 1.1 1.0 0.8
ALFENTANIL	0.6 0.6 0.7 0.8 0.8 0.8 1.1 1.1 1.1 1.1 0.7
PROPOFOL $\mu\text{g}/\text{kg}/\text{min}$	36 43 43 43 21 7
SEDATION SCORE	11 11 11 12 9 7 6 7 7 7 8 8 11 12 13
SERUM CREATININE	68 68 67 77 88 93 79 72 62 64 58 60 54 53

changed to inhalational isoflurane and an alfentanil infusion for analgesia. This regimen was used for 5 days. The inspired concentrations of isoflurane required to achieve a sedation score of 8 were constant (0.8 to 1.0%).

Serial serum fluoride estimations were performed (Table 1). No deterioration in cardiovascular or renal parameters was observed during the use of isoflurane.

After discontinuing isoflurane, sedation was achieved using infusions of midazolam, propofol and alfentanil. Weaning from mechanical ventilation began 11 days later. He was finally discharged to a ward after 11 days.

Fig. 4 Patient D. The drugs given for sedation on a daily basis with the day after admission displayed across the top. All drug doses are in $\mu\text{g}/\text{kg}$ per min except isoflurane, which is shown as a percentage. Serum creatinine is in $\mu\text{mol}/\text{l}$

PATIENT D		DAYS AFTER ADMISSION													
		14	15	16	17	18	19	20	21	22	23	24	25	26	27
INFUSION RATE															
MIDAZOLAM		5.3	6.9							6.3	6.3	6.3	6.3		
FENTANYL		.08	.16							.16	.18	.18	.18		
ISOFLURANE			0.6	1.0	0.8	1.0	1.2	1.2	1.0						
MORPHINE				4.2	5.3	5.3	3.7	3.7	3.7						
PROPOFOL										93	106	106	106		
$\mu\text{g}/\text{kg}/\text{min}$															
SEDATION SCORE		12	9	6	6	6	6	6	6	10	6	6	6		
SERUM CREATININE		36	39	39	0	35	37	40	52	45	35	33	37		

Patient D

A 26-year-old woman was admitted to the ICU following a caesarean section, laparotomy and small bowel resection for volvulus. She required mechanical ventilation of the lungs. Sedation was poorly controlled (score of 12) using a combination of infusions of midazolam and fentanyl (Fig. 4). Inhalational isoflurane (0.8 to 1%) replaced the use of midazolam. A morphine infusion was chosen to replace the fentanyl and was administered for 7 days. Throughout its use, the sedation score was constant.

Serial serum fluoride estimations were performed (Table 1).

Patient E

A 54-year-old obese (140 kg) woman was admitted to the ICU with multiple organ failure, following revision of a vertical banding gastroplasty. She required mechanical ventilation of the lungs.

Sedation and analgesia were initially satisfactorily achieved using infusions of propofol and fentanyl (Fig. 5). This produced a sedation score of 9. Isoflurane was introduced after 5 days and the fentanyl infusion continued. Adequate sedation was obtained with an inspired isoflurane concentration of 1% (sedation score 7).

Serial serum fluoride estimations were performed (Table 1). During the period of use there was no deterioration in creatinine clearance. She died 11 days after admission due to overwhelming sepsis.

PATIENT E		DAYS AFTER ADMISSION									
		4	5	6	7	8	9	10	11	12	13
INFUSION RATE											
PROPOFOL			9.5	24							
FENTANYL			.06	.08	.11	.05	.05	.05	.07	.08	
ISOFLURANE (%)				1.0	0.8	1.0	0.8	1.0	1.0		
$\mu\text{g}/\text{kg}/\text{min}$											
SEDATION SCORE		9	9	9	6	6	7	6			
SERUM CREATININE		150	147	144	149	152	145	133			

Fig. 5 Patient E. The drugs given for sedation on a daily basis with the day after admission displayed across the top. All drug doses are in $\mu\text{g}/\text{kg}$ per min except isoflurane, which is shown as a percentage. Serum creatinine is in $\mu\text{mol}/\text{l}$

Discussion

Sedation of the critically ill patient is often a problem, for which there is no currently available ideal agent. Isoflurane (a fluorinated ether) possesses many of the prop-

erties of the ideal agent. It has been used to provide safe and reliable sedation with minimal side-effects [1, 3, 10].

In our patients it provided good, reliable sedation with predictable inspired concentrations. Awakening, when ap-

appropriate, was rapid – in less than 15 min. There was no evidence of acute tolerance to the sedative effects, even after 8 days' use.

The use of an inhalational anaesthetic for long-term sedation in the critically ill patient has a long history. Previous examples (e.g. nitrous oxide) have led us to expect problems to arise with long-term use. The main potential for toxicity with isoflurane relates to the production of fluoride ions during the metabolism of the agent. In previous work on the nephrotoxicity of methoxyflurane [6], a serum fluoride concentration of $50 \mu\text{mol l}^{-1}$ was reported to be the threshold associated with subclinical laboratory evidence of renal toxicity as evidenced by beginning signs of hypernatraemia, serum hyperosmolality and an increase in urea and urine volume [6].

It also identified plasma concentrations of $100 \mu\text{mol l}^{-1}$ to be associated with evidence of renal impairment on routine biochemical testing [6]. Clinical renal impairment developed if the plasma concentration exceeded $120 \mu\text{mol l}^{-1}$ [6].

The fluoride levels in our patients should also be considered in relation to other reference ranges. The normal serum fluoride level is $<50 \mu\text{g l}^{-1}$ or $<2.6 \mu\text{mol l}^{-1}$ [11]. This is compatible with our two pre-isoflurane fluoride concentrations.

The therapeutic range recommended for fluoride treatment of osteoporosis is $5.3\text{--}13.2 \mu\text{mol l}^{-1}$, although some people have tried levels up to $30 \mu\text{mol l}^{-1}$.

Wide variability has been noticed in the individual fluoride levels after equivalent methoxyflurane exposure. This was attributed to genetic variability and enzyme induction [6].

The fluoride levels obtained in our patients were all below the threshold level of $50 \mu\text{mol l}^{-1}$, and we were unable to demonstrate any new renal dysfunction which could be attributed to isoflurane, even after 8 days' use.

From the limited results available, there is a wide variation in the fluoride levels. It has been postulated that variation in production of inorganic fluoride ions is a reflection of such factors as degree of hepatic enzyme induction and age [6].

It is of interest that the patients (B, C and D) with the highest serum fluoride concentration also had significantly elevated γ -glutamyl transpeptidase concentrations. Patient C had a tenfold increase in the serum fluoride concentration over the 4 days.

Other concerns about the use of isoflurane stem from its high cost, particularly if a low flow circuit is not em-

ployed, and the difficulties associated with the scavenging of spent gases. In order to minimise both of these, we used the Ohmeda Modulus II Plus Anaesthesia System, with a low fresh gas flow and the circle system. Ventilation and monitoring was by the integral Ohmeda 7810 Ventilator and Ohmeda 5250 Respiratory Gas Monitor (BOC Healthcare). Using such a system, the difference in cost compared to conventional intravenous agents is minimal.

In conclusion, isoflurane produced satisfactory and reliable sedation in five critically ill patients, with inspired concentrations of $<1\%$ for up to 7 days. A deterioration in renal function, either biochemically or clinically, could not be attributed to the use of isoflurane in any patient. The direct association between the serum inorganic fluoride concentration and renal dysfunction in the critically ill patient has still to be defined.

In view of the rapid rate of the rise of the fluoride ion concentration in one patient, we recommend regular measurement of the serum inorganic fluoride ion concentration if isoflurane is used for more than 4 days.

Appendix

Sedation score: four point scoring system. A composite score is made from the parameters below. Aim for a score of 8

- A Eyes open
 - 4 Spontaneously
 - 3 To speech
 - 2 To pain
 - 1 None
- B Response to nursing procedures
 - 4 Obeys commands
 - 3 Purposeful movement
 - 2 Non-purposeful movement
 - 1 None
- C Cough
 - 4 Spontaneous and strong
 - 3 Spontaneous and weak
 - 2 On suction only
 - 1 None
- D Respirations
 - 5 Spontaneous extubated
 - 4 Spontaneous intubated
 - 3 SIMV triggering
 - 2 Weak or occasional respiratory action bearing no relationship to ventilation
 - 1 No respiratory efforts

References

1. Kong KL, Willatts SM, Prys-Roberts C (1989) Isoflurane compared with midazolam for sedation in the intensive care unit. *BMJ* 298:1277–1280
2. Beechey APG, Hull JM, McLellan I, Atherley DW (1988) Sedation with isoflurane. *Anaesthesia* 43:419–420
3. Breheny FX, Kendall PA (1992) Use of isoflurane for sedation in intensive care. *Crit Care Med* 20:1062–1064
4. Park GR, Burns AM (1989) Isoflurane compared with midazolam in the intensive care unit. *BMJ* 298:1642
5. Willatts SM, Prys-Roberts C, Kong KL, Spencer EM (1989) Isoflurane compared with midazolam in the intensive care unit. *BMJ* 299:389
6. Cousins MJ, Mazze RI (1973) Methoxyflurane nephrotoxicity. A study of dose response in man. *JAMA* 225:1611–1616
7. Bone RC, Sprung CL, Sibbald WJ (1992) Definitions for sepsis and organ failure. *Crit Care Med* 20:724–726
8. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE (1967) Acute respiratory distress in adults. *Lancet* II:319–323
9. Eddleston JM, Pollard BJ, Blades JF, Doran B (1995) Use of propofol for sedation of critically ill patients undergoing haemofiltration. *Intensive Care Med* 21:342–347
10. Kong KL, Willatts SM, Prys-Roberts C (1989) Isoflurane compared with midazolam for sedation in the intensive care unit. *BMJ* 298:1277–1280
11. Fry BW, Taves DR (1970) Serum fluoride analysis with the fluoride electrode. *J Lab Clin Med* 75:1020–1025